ReviewPhytotherapy research : PTR2026
Exploring Linalool-Based Phytotherapy for Excitatory/Inhibitory Imbalance in Alzheimer's Disease: A Review of Lavender and Cannabis Therapeutic Effects on Sleep, Seizures, and Cognition.
Review in Phytotherapy research : PTR, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
Alzheimer's disease (AD) is a progressive neurodegenerative disorder characterized by cognitive decline, memory impairment, and behavioral disturbances. While its pathogenesis is complex, increasing evidence supports the role of an imbalance between excitatory and inhibitory (E/I) neuronal activity in disease progression. E/I imbalance contributes to synaptic impairment, network hypersynchrony, and ultimately cognitive deterioration. Despite advances in understanding AD pathophysiology, no highly effective or disease-modifying treatments are currently available. This review explores the pharmacological properties of linalool, a monoterpene found in high concentrations in Lavandula angustifolia and in Cannabis sativa L. as minor component, which has demonstrated several neuromodulatory effects. Unlike current AD therapies that typically target cholinergic or NMDA-mediated mechanisms in isolation, linalool exerts a multi-target action that may help restore E/I balance. These effects also underlie its well-established anxiolytic and sedative properties, though their therapeutic relevance extends beyond behavioral symptoms to include the modulation of neuronal network function in neurodegeneration. We also examine studies on lavender extracts, rich in linalool, with the potential to influence sleep regulation, neuronal excitability, and cognitive function. Finally, we discuss the emerging role of cannabis extracts and the potential entourage effect of linalool and phytocannabinoids in targeting neuronal excitability. Overall, the findings discussed in the present review highlight linalool-containing phytocomplexes as promising candidates for supportive or complementary strategies in managing E/I imbalance and cognitive decline in AD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.